Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Affective neural signatures do not distinguish women with emotion dysregulation from healthy controls: A mega-analysis across three task-based fMRI studies.

Neuroimage. Reports·2025

Same author

Adaptive Deep Brain Stimulation in Parkinson's Disease: A Delphi Consensus Study.

medRxiv : the preprint server for health sciences·2024

Same author

The economic benefit of timely, adequate, and adherence to Parkinson's disease treatment: the Value of Treatment Project 2.

European journal of neurology·2020

Same author

Insufficiency of trunk extension and impaired control of muscle force in Parkinson's disease with camptocormia.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2020

Same author

Discrimination of physiological tremor from pathological tremor using accelerometer and surface EMG signals.

Technology and health care : official journal of the European Society for Engineering and Medicine·2020

Same author

Differences in neurology residency training programmes across Europe - a survey among the Residents and Research Fellow Section of the European Academy of Neurology national representatives.

European journal of neurology·2020

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

[Deep brain stimulation for Parkinson's disease].

J Herzog¹, G Deuschl

¹Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 10, Kiel, Germany.

|April 28, 2010

Summary

This summary is machine-generated.

Deep brain stimulation (DBS) effectively treats Parkinson's disease motor symptoms. However, subthalamic nucleus DBS has severe psychiatric side effects, prompting research into alternatives like pallidal DBS.

More Related Videos

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Published on: January 6, 2011

Related Experiment Videos

Last Updated: Jun 13, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Published on: January 6, 2011

Area of Science:

Neurosurgery
Neurology
Movement Disorders

Context:

Deep brain stimulation (DBS) is a primary neurosurgical intervention for Parkinson's disease (PD) motor symptoms.
Subthalamic nucleus DBS (STN-DBS) significantly alleviates motor deficits and enhances quality of life in PD patients.
STN-DBS is linked to serious adverse effects, notably psychiatric issues like depression and increased suicidality.

Purpose:

To evaluate the efficacy and safety of different DBS targets for Parkinson's disease.
To compare subthalamic nucleus DBS with pallidal DBS for motor symptom management and adverse effect profiles.
To explore alternative DBS targets beyond the subthalamic nucleus for PD treatment.

Summary:

STN-DBS effectively reduces Parkinson's disease motor symptoms but carries risks of psychiatric adverse effects.
Pallidal DBS presents a potential alternative with comparable efficacy and a potentially improved safety profile regarding psychiatric symptoms.
Further prospective studies are required to directly compare STN-DBS and pallidal DBS outcomes.
Investigating alternative targets like the pedunculopontine nucleus, thalamic CM/Pf complex, and zona incerta is crucial for advancing PD treatment.

Impact:

Highlights the trade-offs between efficacy and safety in current DBS therapies for Parkinson's disease.
Informs clinical decision-making regarding the choice of DBS target for individual PD patients.
Guides future research directions for optimizing DBS therapy and identifying novel targets for Parkinson's disease.
Emphasizes the need for personalized treatment strategies considering both motor and psychiatric well-being in PD management.